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Background: Hepatitis C virus (HCV) is a major global health problem, causing chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma. Development of well-tolerated regimens with high cure rates and fewer side effects is still
much needed. Recently, natural antimicrobial peptides (AMPs) are attracting more attention as biological compounds
and can be a good template to develop therapeutic agents, including antiviral agents against a variety of viruses.
Various AMPs have been characterized from the venom of different venomous animals including scorpions.
Methods: The possible antiviral activities of crude venoms obtained from five Egyptian scorpion species (Leiurus
quinquestriatus, Androctonus amoreuxi, A. australis, A. bicolor and Scorpio maurus palmatus) were evaluated by a cell
culture method using Huh7.5 cells and the J6/JFH1-P47 strain of HCV. Time-of-addition experiments and inactivation of
enzymatic activities of the venoms were carried out to determine the characteristics of the anti-HCV activities.
Results: S. maurus palmatus and A. australis venoms showed anti-HCV activities, with 50% inhibitory concentrations
(IC50) being 6.3 ± 1.6 and 88.3 ± 5.8 μg/ml, respectively. S. maurus palmatus venom (30 μg/ml) impaired HCV infectivity in
culture medium, but not inside the cells, through virocidal effect. The anti-HCV activity of this venom was not inhibited
by a metalloprotease inhibitor or heating at 60°C. The antiviral activity was directed preferentially against HCV.
Conclusions: S. maurus palmatus venom is considered as a good natural source for characterization and development
of novel anti-HCV agents targeting the entry step. To our knowledge, this is the first report describing antiviral activities
of Egyptian scorpion venoms against HCV, and may open a new approach towards discovering antiviral compounds
derived from scorpion venoms.
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Hepatitis C virus (HCV) infection is a major global health
problem, with estimated more than 170 million infected
individuals worldwide. HCV is an enveloped, positive-
strand RNA virus that belongs to the Hepacivirus genus of
the Flaviviridae family [1-3]. HCV infection is the serious
cause of chronic hepatitis, hepatic steatosis, liver cirrhosis
and eventually hepatocellular carcinoma after a few de-
cades. There is no anti-HCV vaccine available and thera-
peutic options are still limited. The current standard
therapy, which is based on pegylated interferon and ribavi-
rin, is only partially effective, resulting in a sustained* Correspondence: hotta@kobe-u.ac.jp
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unless otherwise stated.virological response (SVR) in about 50% of patients and
has considerable side effects [1,3]. Recently, HCV NS3
protease inhibitors and NS5A inhibitors have been ap-
proved for clinical use and SVR rates have improved to
reach 70% or higher [4-8]. However, these therapies are
quite expensive and will probably not be accessible for all
patients worldwide. For this reason, the development of
new classes of safe and inexpensive antiviral compounds
with improved efficacy is still needed for treatment of
HCV infections.
Recently, natural antimicrobial peptides (AMPs) are
attracting more attention as therapeutic agents against a
variety of microbes including antibiotics-resistant strains
[9,10]. Most AMPs share certain common features such
as being small peptides of 10 to 50 amino acid residues,
containing positive charge of 2 to 9 residues and anThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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broad spectrum of antiviral and antibacterial activities,
with direct or indirect microbicidal activities [12]. AMPs
have been isolated from venomous animals including
scorpions. Scorpion venoms consist of a cocktail of bio-
logically active peptides that represent a tremendous po-
tential for use in drug design and development [14-17].
Most scorpion venom peptides are composed of 20 to
75 amino acid residues while certain proteins, enzymes,
consist of 120 to 370 residues [17]. Scorpion venom pep-
tides show a vast array of biochemical activities and
pharmacological functions. They can be classified into two
classes, i.e., disulfide-bridged and non-disulfide-bridged
peptides [18-20]. AMPs found in scorpion venoms are
paid more and more attention due to their unique bio-
logical activities that can potentially be used as broad-
spectrum antiviral agents [9,21-28]. Scorpion venom
AMPs are positively charged amphipathic peptides and
can be divided into three structural categories: (i) cysteine
containing peptides with disulfide bridges; (ii) peptides
with an amphipathic α-helix but lacking cysteine residues
and (iii) peptides rich in certain amino acids such as pro-
line and glycine [29].
The list of Egyptian scorpions currently includes 24 spe-
cies classified under 13 genera within four different families,
Buthidae, Diplocentridae, Euscorpiidae and Scorpionidae
[30]. In the present study, we screened crude venoms ob-
tained from five Egyptian scorpion species, Leiurus quin-
questriatus, Androctonus amoreuxi, A. australis, A. bicolor
and Scorpio maurus palmatus, for possible anti-HCV activ-
ities using an HCV cell culture system. We report here that
crude venoms of S. maurus palmatus, and A. australis to a
lesser extent, possess antiviral activities against HCV. To
our knowledge, this is the first report describing anti-HCV
activities of Egyptian scorpion venoms.
Results
Screening of anti-HCV activities of scorpion venoms
Anti-HCV activities of crude venoms of five Egyptian
scorpion species were tested. As shown in Table 1, A.
australis and S. maurus palmatus showed anti-HCVTable 1 Antiviral activity (IC50) against HCV, cytotoxicity
(CC50) and selectivity index (SI) of crude venoms of five




Leiurus quinquestriatus >100 >100 na
Androctonus amoreuxi >100 >100 na
Androctonus australis 88.3 ± 5.8 >300 >3.4
Androctonus bicolor >100 >100 na
Scorpio maurus palmatus 6.3 ± 1.6 >100 >15.8
a: Data represent means ± SEM of the data obtained from two independent
experiments using the J6/JFH1-P47 strain of HCV.
na: Not applicable.activities, with IC50 being 88.3 ± 5.8 and 6.3 ± 1.6 μg/ml,
respectively. Their CC50 were >300 and >100 μg/ml, re-
spectively, with their selectivity indexes (SI; CC50/IC50)
being >3.4 and >15.8, respectively. Crude venoms of the
other three scorpion species did not exhibit significant
anti-HCV activities at the concentration of 100 μg/ml.
Dose-dependent anti-HCV activity of S. maurus palma-
tus is shown in Figure 1.
HCV inhibitory mechanisms of the S. maurus palmatus
venom
To further explore the mode of action of the S. maurus
palmatus venom, time-of-addition experiments were
performed. In brief, S. maurus palmatus crude venom
(30 μg/ml) was added to the virus and/or cells at differ-
ent time points relative to virus inoculation, as described
in the Methods section: (i) pre-treatment of cells for
2 hr (−2 hr cells). This experiment examines whether
there is any interaction between the venom and the cells.
(ii) pre-treatment of virus for 2 hr (−2 hr virus). This ex-
periment examines the possible virocidal activity of the
venom. (iii) co-treatment of cells and virus during virus
inoculation for 2 hr (0 hr). This experiment examines
the antiviral effect at the entry step. (iv) treatment of
virus-infected cells during post-inoculation for 46 hr
(+2 hr). This experiment examines the antiviral effect
during the post-entry step. (v) co-treatment and post-
inoculation (0 hr & +2 hr) as a positive control. For each
set of experiments, HCV infectivity in culture superna-
tants was determined and compared with each other.1 00101 25 50
Venom conc. (µg/ml)  
0
20
Figure 1 Dose-dependent anti-HCV activity of S. maurus
palmatus venom. A fixed amount of HCV was mixed with serial
dilutions of S. maurus palmatus venom and inoculated to Huh7.5 cells
at a multiplicity of infection of 0.5 pfu/cell. After virus adsorption, the
cells were cultured with the same concentrations of the venom for
46 hr. The culture supernatants were harvested and titrated for virus
infectivity. Percent inhibitions of HCV infectivity by the venom at the
concentrations of 0.1 to 100 μg/ml are shown. Data represent means ±
SEM of the data obtained from two independent experiments.
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(−2 hr virus) markedly suppressed production of HCV
infectious particles in culture supernatants while pre-
treatment of cells for 2 hr (−2 hr cells) only marginally sup-
pressed it (Figure 2A). This suggested the possibility that S.
maurus palmatus venom had direct virocidal activity. Also,
treatment during post-inoculation for 46 hr (+2 hr) sup-
pressed HCV infectivity in culture supernatants, though to
a lesser extent compared to pre-treatment of virus for 2 hr
(−2 hr virus). The result suggested that this treatment
inhibited either HCV replication in the cell or HCV infect-
ivity outside the cells (in culture supernatants). On the
other hand, treatment during post-inoculation for 46 hr
(+2 hr) did not significantly inhibit HCV NS3 protein ac-
cumulation while pre-treatment of virus for 2 hr (−2 hr
virus) completely inhibited it at 1 and 2 days post-infection






















































































Figure 2 Analysis of mode-of-action of S. maurus palmatus venom. Hu
palmatus venom (30 μg/ml) at different time points as indicated (A, B) or l
the supernatants. Data represent means ± SEM of the data obtained from two i
untreated control; §, below the detection limit; dpi, days post-infection. (B) HCV
to immunoblot analysis using monoclonal antibody against the HCV NS3 prote
verify equal amounts of sample loading. Signal intensities of NS3 were normaliz
cells. The venom treatment was done only during the post-inoculation (+2 hr) s
Amounts of HCV infectious particles inside the cells. The venom treatment was
subjected to 3 cycles of freezing and thawing at −80°C and 37°C, respectively, aand virus infectivity inside the cells. The result revealed
that the post-inoculation treatment (+2 hr) did not signifi-
cantly inhibit HCV RNA replication in the cells (Figure 2C).
Moreover, the venom treatment (+2 hr) did not reduce
HCV infectivity inside the cells (Figure 2D). Taken to-
gether, these results suggest that the S. maurus palmatus
venom acts directly on HCV particles in culture medium
to impair the viral infectivity and that it does not exert its
antiviral effect inside the cells.
Effects of neutralization of the proteinase activity by
heating and/or a metalloproteinase inhibitor
In order to investigate whether anti-HCV activity of S.
maurus palmatus venom involves an enzymatic activity,
we treated the venom (30 μg/ml) with heating at 60°C for
20 min or a metalloproteinase inhibitor, 1, 10-phenan-
throline (5 mM) to inactivate them, as reported by other3




















1 dpi 2 dpi
Control
Venom
h7.5 cells were infected with HCV and treated with S. maurus
eft untreated as a control. (A) Amounts of HCV infectious particles in
ndependent experiments. *, P <0.05; †, P <0.001, compared with the
NS3 protein accumulation in the cells. Virus-infected cells were subjected
in at 1 and 2 days post-infection. GAPDH served as an internal control to
ed to the corresponding GAPDH signal. (C) Amounts of HCV RNA in the
tep. HCV RNA amounts were normalized to GAPDH mRNA expression. (D)
done only during the post-inoculation (+2 hr) step. Virus-infected cells were
nd HCV infectivity inside the cells was measured.
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HCV and incubated for 2 hr at 37°C. Then, the virus/
venom mixture was inoculated to Huh7.5 cells and virus
replication was analyzed. The results obtained revealed
that the treated venom, either treated with heating at 60°C
or the metalloproteinase inhibitor, or both at the same
time, still markedly suppressed production of HCV infec-
tious particles in the culture to the same extent compared
to the untreated control (Figure 3A). Consistent with this
observation, accumulation of intracellular HCV NS3 pro-
tein was also inhibited (Figure 3B).
Specificity of antiviral activity of S. maurus palmatus
venom
In order to determine whether or not the antiviral activ-
ity of S. maurus palmatus venom shown above was spe-
cific to HCV, we examined its possible effects on
different viruses, such as dengue virus type 2 [35,36],
measles virus [37] and influenza virus [38]. In this ana-
lysis, each virus was pre-treated with the venom (30 and
60 μg/ml) for 2 hr and the remaining virus infectivity
was measured by infectious center or plaque assay. The
result revealed that the venom exerted only weak inhib-
ition on measles virus but strong inhibition on dengue
virus (Figure 4A). Interestingly, the same venom did not
inhibit but rather enhanced infectivity of influenza virus
(Figure 4B).
Discussion
Venomous animals including scorpions have evolved a



























Figure 3 Effects of neutralization of the proteinase activities of the vi
S. maurus palmatus venom (30 μg/ml) was treated with a metalloproteinas
treated venom was mixed with HCV for 2 hr at 37°C and the mixture was ino
absence of the venom for one day. The culture supernatants were titrated for
using monoclonal antibody against the HCV NS3 protein (B). GAPDH served a
represent means ± SEM of the data obtained from two independent experimand defense [39]. Scorpion venoms are a rich source of
natural peptides and have been recognized as potential
bioactive peptides [24,39,40]. cDNA library sequencing
and proteomics profiling analyses have revealed that a sin-
gle scorpion venom contains more than 100 peptidic com-
ponents ranging in size from 1 to 9 kDa [41,42]. An
increasing number of studies have shown that scorpion
venoms and toxins possess antiviral activities in vitro and
in vivo and are considered as a rich source for developing
effective antiviral drugs [24,26-28,43,44].
In the present study, we screened crude venoms ob-
tained from five Egyptian scorpion species for their pos-
sible anti-HCV activities. We observed that crude venoms
of S. maurus palmatus and A. australis possessed anti-
HCV activities, with their IC50 values being 6.3 ± 1.6 and
88.3 ± 5.8 μg/ml, respectively (Table 1). We also demon-
strated that S. maurus palmatus venom acts directly on
HCV particles in culture supernatants to inhibit the viral
infectivity (Figure 2A), suggesting the inhibition at the
entry step, the first step of HCV life cycle. On the other
hand, it was unlikely that the venom exerted its antiviral
activity inside the cells (Figure 2B-D).
Scorpion venoms contain a wide variety of pharmaco-
logically active peptides and proteins. Some of them pos-
sess enzymatic activities, such as metalloproteases, while
others are non-enzymatic constituents [18,45,46]. It has
been reported that the proteolytic activities of those en-
zymes were almost completely abolished by treatment with
a matrix metalloproteinase inhibitor, 1, 10-phenanthroline
[31,32,47]. Also, those enzymatic activities are known to be





rocidal effects of S. maurus palmatus venom against HCV.
e inhibitor (1, 10-phenan-throline; 5 mM) at 4°C or 60°C for 20 min. The
culated to Huh7.5 cells for 2 hr at 37°C. The cells were cultivated in the
virus infectivity (A) and the cells were subjected to immunoblot analysis
s an internal control to verify equal amounts of sample loading. Data














































Figure 4 Antiviral activity of S. maurus palmatus venom against dengue virus, measles virus and influenza virus. (A) Dengue virus and
measles virus that had been treated with S. maurus palmatus venom (30 and 60 μg/ml) for 2 hr or left untreated as a control were inoculated to
Vero/SLAM cells and cultivated for 24 hr. The number of virus-infected cells was determined by immunofluorescence and plaque assays and the
percentages compared to the untreated control calculated. Data represent means ± SD of the data obtained from triplicate cultures. ‡, ~0.2% of
the control. (B) Influenza virus and HCV that had been treated with S. maurus palmatus venom (30 and 60 μg/ml) for 2 hr or left untreated were
inoculated to MDCK and Huh7.5 cells, respectively. The number of virus-infected cells was determined by immunofluorescence analysis and the
percentages of the numbers of virus-infected cells compared to the untreated control calculated. Data represent means ± SEM of the data
obtained from two independent experiments. *, P <0.05; †, P <0.001, compared with the untreated control. §, <0.01% of the control.
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that treatment of the S. maurus palmatus venom with 1,
10-phenanthroline and/or heating at 60°C for 20 min did
not impair its anti-HCV activity (Figure 3). These results
suggest that the anti-HCV activity of the S. maurus palma-
tus venom is independent of its proteinase activities.
Concerning the molecular mechanism(s) of the anti-
HCV activity, there was a possibility that venom peptides
induced disruption in virus envelope (composed of lipid
bilayer) through making pores in it. If this was the case,
the venom might inhibit other envelope viruses than
HCV. To test this possibility, we used three different vi-
ruses, such as dengue virus type 2 [35,36], another mem-
ber of the family Flaviviridae, and measles virus [37]
and influenza virus [38] that belong to the family Para-
myxoviridae and Orthomyxoviridae, respectively. The re-
sults obtained demonstrated that S. maurus palmatus
venom exerted strong inhibition on dengue virus and
only weak inhibition on measles virus (Figure 4A). On
the other hand, the same venom did not inhibit but ra-
ther enhanced influenza virus infectivity (Figure 4B).
These results exclude the possibility that S. maurus pal-
matus venom inhibits all the envelope viruses, suggest-
ing that the venom preferentially inhibits HCV and
dengue virus, both of which belong to the family Flavi-
viridae, but not other viruses, e.g., influenza virus.S. maurus palmatus venom has been reported to con-
tain about 65 compounds, whose molecular masses vary
from 413 to 14,009 Da, with a majority ranging between
3 and 5 kDa. A variety of putative bioactive molecules
have been identified, such as neurotoxins (NaScTxs and
KScTxs), calcines, La1-like peptides, insecticidal toxins
and other AMPs [40]. Some of the scorpion venom pep-
tides showed antiviral activities against certain viruses,
such as measles virus, SARS coronavirus, H5N1 influ-
enza virus [27], hepatitis B virus [49], herpes simplex
virus 1 [28] and human immunodeficiency virus [50]. As
for anti-HCV peptides from scorpion venoms, Yan et al.
[26] reported that Hp1090 screened from the venomous
gland cDNA library of the scorpion Heterometrus peter-
sii inhibited HCV infection by targeting the viral mem-
brane, disrupting its structural integrity. Also, Hong
et al. [43] identified another anti-HCV peptide Ctry2459
from the venom peptide library of the scorpion Chaeri-
lus tryznai. These peptides exerted a virocidal effect on
HCV and some other viruses. Consistent with those re-
sults, we observed that S. maurus palmatus venom
inhibited infectivity of HCV particles, suggesting direct
virocidal activity of the venom. Interestingly, the anti-
viral activity of S. maurus palmatus venom is likely to be
preferentially directed to HCV and dengue virus, both of
which are members of the family Flaviviridae. Further
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cation analyses are needed to identify an active com-
pound(s) responsible for this antiviral activity.
Conclusions
We screened crude venoms obtained from five Egyptian
scorpion species for anti-HCV activities and demon-
strated that S. maurus palmatus venom inhibits HCV
infectivity through direct virocidal activity. In addition,
this antiviral activity appeared to be independent of pro-
teinase activities of the venom and is directed preferen-
tially against HCV, but not equally against all the
enveloped viruses. To our knowledge, this is the first re-
port describing antiviral activities of Egyptian scorpion
venoms against HCV, and has opened a new approach
towards discovering antiviral compounds derived from
scorpion venoms.
Methods
Scorpions and venom preparation
Adult scorpions were collected from different places in
Egypt. They were fed with cockroaches and received
water. The venoms were obtained from scorpions using
electrical stimulation (12 to 20 V) or by surgically separ-
ating venom glands from smaller scorpions, with the
milked venoms being squeezed out into an Eppendorf
tube using fine forceps, and solubilized in distilled water.
The crude venoms thus obtained were centrifuged at
14,000 rpm for 10 min at 4°C. The supernatants were
pooled, freeze-dried and stored at −20°C. The lyophilized
samples were dissolved in distilled water, centrifuged at
15,000 rpm for 15 min at 4°C and the supernatants were
stored at −20°C until being used. Protein concentrations
of the samples were determined using BCA Protein
Assay Kit (Pierice Biotechnology, USA).
Cell culture and viruses
Huh7.5 cells and the plasmid pFL-J6/JFH1 to produce
the J6/JFH1 strain of HCV genotype 2a [51] were kindly
provided by Dr. C. M. Rice, The Rockefeller University,
New York, NY, USA. Huh7.5 cells were cultivated in
Dulbecco’s modified Eagle’s medium (Wako, Osaka,
Japan) supplemented with fetal bovine serum (Biowest,
Nuaille, France), non-essential amino acids (Invitrogen,
Carlsbad, CA, USA), penicillin (100 IU/ml) and strepto-
mycin (100 μg/ml) (Invitrogen). Cells were grown at 37°C
in a 5% CO2 incubator. The J6/JFH1-P47 strain [51] of
HCV genotype 2a propagated in Huh7.5 cells was used in
this study.
Dengue virus type 2 (Trinidad 1751 strain) [35,36],
propagated in BHK-21 cells, was inoculated to Vero/
SLAM cells [52]. After virus adsorption for 1 hr, the
virus-infected cells were cultivated in DMEM supple-
mented with 10% fetal bovine serum at 37°C in 5% CO2.Measles virus (K52 strain) [37], propagated in B95a
cells, was inoculated to Vero/SLAM cells. After virus ad-
sorption for 1 hr, the virus-infected cells were cultivated
as described above.
Influenza A virus A/Udorn/307/72 (H3N2) was inoc-
ulated to Madin-Darby canine kidney (MDCK) cells
for 60 min on ice and the virus-infected cells were cul-
tivated in minimum essential medium (MEM; Life
Technologies, Tokyo, Japan) containing 2.5 μg/ml
TPCK-trypsin (Worthington Biochemical Corp., Lake-
wood, NJ, USA) and 100 units/ml each of penicillin
and streptomycin (GIBCO, Gland Island, NY, USA) at
37°C in 5% CO2.
Analysis of antiviral activities of crude venoms
Huh7.5 cells were seeded in 24-well plates (1.6 × 105
cells/well). A fixed amount of HCV was mixed with ser-
ial dilutions of crude venoms (0.1 to 100 μg/ml) and in-
oculated to the cells. After 2 hr, the cells were washed
with medium to remove the residual virus and further
incubated in medium containing the same concentra-
tions of the crude venoms as those used during virus in-
oculation. Culture supernatants were obtained at 1 and
2 days post-infection (dpi) and titrated for virus infectivity.
Virus and cells treated with medium served as controls.
Percent inhibition of virus infectivity by the samples was
calculated by comparing with the controls and 50% inhibi-
tory concentrations (IC50) were determined.
Virus titration
HCV infectivity was determined as described previously
[53]. In brief, virus samples were diluted serially 10-fold
in complete medium and inoculated onto Huh7.5 cells
seeded on glass coverslips in a 24-well plate. After virus
adsorption for 2 hr, the cells were washed with medium to
remove residual virus and cultured for 24 hr. The virus-
infected cells were washed with phosphate-buffered saline
(PBS), fixed with 4% paraformaldehyde for 20 min and
permeabilized with 0.1% Triton X-100 in PBS for 15 min
at room temperature. After being washed three times with
PBS, the cells were incubated with HCV-infected patient’s
serum for 1 hr, followed by incubation with FITC-
conjugated goat anti-human IgG (Medical & Biological
Laboratories Co., Ltd., Nagoya, Japan). The cells were
counterstained with Hoechst 33342 (Molecular Probes,
Eugene, OR, USA) for 5 min and HCV-infected cells were
counted under a BZ-9000 fluorescence microscope (Key-
ence, Osaka, Japan).
To determine intracellular HCV infectivity, freeze-and-
thaw experiments were performed. In brief, virus-infected
cells were washed with PBS, harvested by trypsin treat-
ment and centrifuged at 1,250 rpm for 5 min at 20°C. The
cell pellets obtained were resuspended in 400 μl of fresh
medium and subjected to 3 cycles of freezing and thawing
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samples were centrifuged at 3,000 rpm for 10 min at 4°C
to remove cell debris, and HCV infectivity was measured
by immunofluorescence staining, as described above.
To determine dengue virus infectivity, serially diluted
virus was inoculated to Vero/SLAM cells and cultivated
for 24 hr. The cells were subjected to indirect immuno-
fluorescence analysis using mouse monoclonal antibody
against dengue virus followed by Alexa Fluor A488 goat
anti-mouse IgG (Life Technologies), as described above,
and the number of infected cells counted.
Measles virus was inoculated to Vero/SLAM cells and
cultivated for 24 hr. Plaques (virus-induced syncytia)
forming on the monolayer cells were counted.
Influenza virus was inoculated to MDCK cells and culti-
vated for 6 ~ 8 hr. The cells were fixed with 4% parafor-
maldehyde for 10 min followed by cold methanol (−30°C)
for 5 min at room temperature. The fixed cells were incu-
bated for 30 min with rabbit polyclonal antibody raised
against purified influenza virus (A/Udorn/307/72 strain)
[38]. After two washes, the cells were incubated for
30 min with Alexa Fluor A488 goat anti-rabbit IgG (Life
Technologies) and Hoechst 33342 (to counterstain nuclei
of all cells). The coverslips were mounted on a slide glass
with Vectashield H-1000 reagent (Vector Laboratories,
Inc. Burligame, CA) and observed using a fluorescence
microscope.
Time-of-addition experiments
The crude venom was added at a final concentration of
30 μg/ml to the virus or cells at different time points
relative to virus inoculation. Five sets of experiments
were performed in parallel: (i) Pre-treatment of cells
(−2 hr cells): venom was added to the cells for 2 hr at
37°C followed by washing two times with medium before
virus infection and incubated with medium without
venom for 46 hr. (ii) Pre-treatment of virus (−2 hr virus):
the virus was mixed with the venom for 2 hr at 37°C,
and then the mixture was inoculated to the cells for 2 hr
at 37°C. After the virus/venom mixture was removed by
washing two times, the cells were incubated with
medium without venom for 46 hr. (iii) Co-treatment of
cells and virus during virus inoculation (0 hr): Virus/
venom mixture was inoculated to the cells and incu-
bated for 2 hr. After the virus/venom mixture was re-
moved by washing two times, the cells were incubated
with medium without venom for 46 hr. (iv) Treatment
during post-inoculation (+2 hr): Cells were infected with
the virus for 2 hr in the absence of the venom. After the
virus was removed by washing two times, the cells were
incubated with medium containing the venom for 46 hr.
(v) Co-treatment during inoculation and post-inoculation
(0 hr & +2 hr): As a positive control, virus/venom mixture
was inoculated to the cells and incubated for 2 hr. Afterthe virus/venom mixture was removed by washing two
times, the cells were incubated with medium containing
the venom for 46 hr. In each set of experiments, the su-
pernatants were collected and titrated for virus infectivity.
Also, the cells were subjected to immunoblot analysis for
intracellular accumulation of viral and host proteins.
WST-1 assay for cytotoxicity test
WST-1 assay was performed as described previously
with a slight modification [53]. In brief, Huh7.5 cells
plated in 96-well plates were treated with serial dilutions
of crude venoms or complete medium as a control for
48 hr at 37°C. After this treatment, 10 μl of WST-1 re-
agent (Roche, Mannheim, Germany) was added to each
well and the cells were cultured for 4 hr. The WST-1 re-
agent is absorbed by the cells and converted to formazan
by mitochondrial dehydrogenases. The amount of for-
mazan, which correlates with the number of living cells,
was determined by measuring the absorbance of each
well using a microplate reader at 450 and 630 nm. Per-
cent cell viability compared to the control was calculated
for each dilution of the venoms and 50% cytotoxic con-
centrations (CC50) were determined.
Immunoblot analysis
Cells were lysed with SDS sample buffer and equal
amounts of protein were subjected to SDS–polyacryl-
amide gel electrophoresis. The separated proteins were
transferred onto a polyvinylidene difluoride membrane
(Millipore, Bedford, MA, USA). The membrane was
blocked by incubation with 5% skim milk and incubated
with the respective primary antibodies. The primary
antibodies used were mouse monoclonal antibodies
against HCV NS3 and GAPDH (Millipore). Horseradish
peroxidase-conjugated goat anti-mouse immunoglobulin
(Invitrogen) was used to visualize the respective proteins
by means of an enhanced chemiluminescence detection
system (ECL; GE Healthcare, Buckinghamshire, UK).
Real-time quantitative RT-PCR
Total RNA was extracted from the cells using a Relia-
Prep RNA cell miniprep system (Promega, Madison,
WI, USA) according to the manufacturer’s instructions.
One μg of total RNA was reverse transcribed using a
GoScript Reverse Transcription system (Promega) with
random primers and subjected to quantitative real-time
PCR analysis using SYBR Premix Ex Taq (TaKaRa,
Kyoto, Japan) in a MicroAmp 96-well reaction plate and
an ABI PRISM 7500 system (Applied Biosystems, Foster
City, CA, USA). The primers used to amplify an NS5A re-
gion of the HCV genome were 5′-AGACGTATTGAGGT
CCATGC-3′ (sense) and 5′ CCGCAGCGACGGTGCT
GATAG-3′ (antisense). As an internal control, human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
El-Bitar et al. Virology Journal  (2015) 12:47 Page 8 of 9gene expression levels were measured using primers
5′ GCCATCAATGACCCCTTCATT-3′ (sense) and 5′
TCTCGCTCCTGGAAGATGG-3′.Neutralization of the proteinase activities of scorpion
crude venom by heating and a metalloproteinase
inhibitor
Crude venom (30 μg/ml) was heated at 60°C for 20 min
or treated with a metalloprotease inhibitor (1,10-phe-
nanthroline; 5 mM) [31-34] at 4°C or 60°C for 20 min.
The treated venom or untreated control was mixed with
HCV for 2 hr at 37°C. The virus/venom mixture was
then inoculated to Huh7.5 cells for 2 hr at 37°C. After
the virus inoculation, the cells were washed three times
and incubated with medium without venom. After 48 hr,
culture supernatants were collected and virus infectivity
was titrated. The virus-infected cells were subjected to
immunoblot analysis to check the level of HCV protein
accumulation, as described above.Statistical analysis
Data are representative of at least 2 independently re-
peated experiments and presented as mean ± SEM. The
statistical significance was examined using Student’s t-
test. P value of <0.05 was considered significant.
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